Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline Landscape | DelveInsight
August 02, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs,...
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET
|
Icosavax, Inc.
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Respiratory Syncytial Virus Therapeutics Market worth USD 4,003.4 Million at 30.9% CAGR; Varying Ethnicity and Climate Difference to Boost Demand in Asia Pacific
January 20, 2021 08:42 ET
|
Fortune Business Insights
Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global Respiratory Syncytial Virus Therapeutics Market size is estimated to showcase potential growth owing to its increasing adoption against the...